Clustering of rheumatoid arthritis patients: an unsupervised machine learning approach for characterizing the TNFi response.

Authors

Pedro Augusto Silva Dos Santos Rodrigues, Katarina Mattos Brandão, Lilian de Sá Garcia Landeiro, Laryssa Cardoso Calmon, Almirane Lima de Oliveira, Thamara Barbosa Miranda, João Locke Ferreira de Araújo, Rafael Valente Veiga, Camila Alexandrina Viana de Figueiredo, Pablo de Moura Santos, Ryan Dos Santos Costa

Published in

Immunologic research. Volume 74. Issue 1. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

This study aimed to identifydistinct profiles of response to Tumor Necrosis Factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients using unsupervised machine learning to integrate clinical, demographic, and genetic data. A cohort of 294 RA patients was analyzed using hierarchical clustering techniques. Data collected included body mass index (BMI), adherence to physical activity, prevalence of comorbidities, seropositivity, Health Assessment Questionnaire (HAQ) scores, and genetic polymorphisms in TNF pathway. Responders to TNFi demonstrated a more favorable clinical profile, with a lower BMI (25.6 vs. 27.0; p = 0.03), higher physical activity adherence (56.6% vs. 33.3%; p < 0.01), reduced prevalence of comorbidities (69.8% vs. 82.4%; p = 0.02), and improved functionality (HAQ: 0.8 vs. 1.7; p < 0.01) compared with non-responders. The C allele of rs767455 was significantly more frequent among responders (74.4% vs. 62.4%; p = 0.04). Clustering analysis identified three distinct subgroups: a better prognosis group characterized by a 73.5% response rate, minimal use of combination therapies, high adherence to physical activity, and male predominance; a poorer therapeutic response group with 82.9% therapeutic failure, intensive medication use, and low exercise adherence; and an intermediate group. TNFi response in RA is multifactorial. Integrating clinical, demographic, and genetic data enables the identification of distinct patient profiles, supporting the development of personalized treatment strategies and the advancement of precision medicine in RA management.

PMID:
42606794
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.